Placeholder Banner

BIO Comments on FDA Draft Guidance on Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases

February 16, 2018

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases.

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) provide new pediatric information in labeling for over 600 products.

BIO appreciates the FDA’s efforts to clarify and provide notice of a policy change intended to enable the FDA to apply the Orphan Drug Act (ODA) and PREA to non-rare adult indications corresponding to orphan-designated pediatric subpopulations. However, BIO’s comments detail general concerns with the guidance and specific line edits to clarify and improve the guidance.

 

Download Full Comments Below
BIO Letter Clarification Of Orphan Designation Of Drugs And Biologics For Pedaitric Subpopulations Of Common Diseases FDA-2017-D-6380
Read full comment letter below
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Solicitation of Input from Stakeholders on Agricultural Innovations. BIO applauds USDA for taking a proactive approach and seeking…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…